Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Qiagen ( (QGEN) ) is now available.
Qiagen N.V. has been notified by the Netherlands Authority for the Financial Markets (AFM) regarding a disclosure involving BlackRock, Inc.’s voting rights and capital interest in the company. The announcement reveals BlackRock’s indirect holdings in Qiagen, with a capital interest of 8.80% and voting rights of 9.88%. This notification may impact Qiagen’s shareholder dynamics, highlighting significant institutional interest from a major financial entity like BlackRock.
More about Qiagen
Qiagen N.V. operates in the biotechnology industry, specializing in providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company focuses on enhancing the capabilities of laboratories to unlock molecular insights for a wide range of applications.
YTD Price Performance: 2.16%
Average Trading Volume: 958,898
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $10.12B
For an in-depth examination of QGEN stock, go to TipRanks’ Stock Analysis page.
